Catalyst News and Research

RSS

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

US biochemist to be honoured with Inhoffen Medal Braunschweig, Germany

How do bacteria cope when exposed to toxic mercury, how are they able to outlast antibiotics, and how can they be killed using so-called "suicide inhibitors?" These are but a few of the many research topics US biochemist Christopher Walsh has devoted his career as a scientist to.

15 Apr 2013

Opinion pieces urge continued support for Global Fund

This week, the Global Fund to Fight AIDS, Tuberculosis and Malaria gathered representatives from donor and implementing countries in Brussels, Belgium, to formally launch its 2014-2016 replenishment process.

12 Apr 2013

Protein EPAC2 plays major role in development of type 2 diabetes

A team of researchers at the Johns Hopkins Children's Center has found that a protein long believed to have a minor role in type 2 diabetes is, in fact, a central player in the development of the condition that affects nearly 26 million people in the United States alone and counts as one of the leading causes of heart disease, stroke and kidney, eye and nerve damage.

12 Apr 2013

New research shows promise in creating chemical reactions necessary for pharmaceutical companies

Shaken, not stirred, is the essence of new research that's showing promise in creating the chemical reactions necessary for industries such as pharmaceutical companies, but eliminating the resulting waste from traditional methods.

10 Apr 2013

Public opinion can be detrimental to soldiers' mental health, says study

Can events like Red Fridays, Tickets for Troops and the yellow ribbon campaign reduce the chances of Canadian soldiers experiencing combat-related stress disorders? The authors of a new study from the University of Alberta think so.

7 Apr 2013

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.

6 Apr 2013

Three institutions partner to create research breakthroughs in children's health

Virginia Tech, Children's National Medical Center, and the George Washington University have partnered in a unique program to create research breakthroughs in children's health.

4 Apr 2013

Kavli Foundation applauds launch of new brain research initiative

The Kavli Foundation applauds today's launch by President Obama of his Administration's ambitious research effort to understand the brain by deciphering the brain's activity that gives rise to our perceptions, our experiences and our consciousness.

3 Apr 2013

Viewpoints: 'Big risks' of buying private insurance with Medicaid dollars; One month of sequestration

The Obama administration and Republican officials in several states are exploring ways to redirect federal money intended to expand Medicaid, the main public insurance program for the poor, and use it instead to buy private health insurance for Medicaid recipients.

2 Apr 2013

CDC to portray impact of COPD in COPD Foundation's anti-smoking ad campaign

The COPD Foundation announces today that the Centers for Disease Control and Prevention will, for the first time, depict the impact of Chronic Obstructive Pulmonary Disease in its national ad campaign, Tips From Former Smokers.

30 Mar 2013

Hospitals often don't tell patients about assistance programs to help pay bills

ABC reports that although nonprofit hospitals are obligated to give back to the community, they often don't ease the strain for patients with financial difficulties. And in other news, The New York Times looks at efforts to cut emergency room care costs.

30 Mar 2013

Adding muscle to plans' push for value-based health care

A survey from Catalyst for Payment Reform, a nonprofit lobbying group comprising highly profitable Fortune 500 giants, found that many of its members do not feel like they are getting the value for which they are paying.

29 Mar 2013

First annual National Scorecard on Payment Reform released

Catalyst for Payment Reform, an independent, non-profit employer coalition pushing for better value in health care, today released its first annual National Scorecard on Payment Reform.

26 Mar 2013

Researchers develop new device to battle against secondhand tobacco smoke

Dartmouth researchers have taken an important step in the ongoing battle against secondhand tobacco smoke. They have pioneered the development of a breakthrough device that can immediately detect the presence of secondhand smoke and even third-hand smoke.

25 Mar 2013

Researchers develop new approach for HIV vaccine development

Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade any vaccine-induced immune response.

22 Mar 2013

Illinois chemists use DNA catalysts to do protein's job

Illinois chemists have used DNA to do a protein's job, creating opportunities for DNA to find work in more areas of biology, chemistry and medicine than ever before.

20 Mar 2013

Ill health and retirement: an interview with Dr Sabrina Pit, University Centre for Rural Health, University of Sydney

In our study population, which was drawn from NSW Australia only, the proportion of working aged men who were fully retired due to ill-health in cities is five percent, eight percent for inner regional areas and nine for outer regional areas.

20 Mar 2013

Synthesis & Solid State Pharmaceutical Centre: an interview with Dr Mary Shire, University of Limerick

This is a new research centre led by the University of Limerick that supports the pharmaceutical sector in Ireland. The centre will carry out research on the key aspects of what it takes to synthesise the pharmaceutically active molecule to isolate a pure material and to formulate this into a medicine.

14 Mar 2013

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria.

12 Mar 2013